Get the Stockscreener App
1.13
1.74%
-0.02
Humacyte Inc stock is traded at $1.13, with a volume of 3.08M.
It is down -1.74% in the last 24 hours and up +10.78% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.15
Open:
$1.12
24h Volume:
3.08M
Relative Volume:
0.59
Market Cap:
$218.09M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.0561
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+11.88%
1M Performance:
+10.78%
6M Performance:
-30.67%
1Y Performance:
-69.87%
1-Day Range:
$1.10
$1.15
1-Week Range:
$1.03
$1.16
52-Week Range:
$0.88
$3.94
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.13 | 221.95M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
What’s the fair value of Humacyte Inc. stock2025 Geopolitical Influence & Short-Term High Return Ideas - mfd.ru
Why Humacyte Inc. stock is favored by top institutions2025 Retail Activity & Fast Gaining Stock Strategy Reports - mfd.ru
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Insider Trends: Should I invest in Humacyte Inc Equity Warrant before earningsJuly 2025 Short Interest & Verified Stock Trade Ideas - baoquankhu1.vn
Humacyte Announces Presentation of Symvess Long-Term Safety and Efficacy Results at VESS Meeting - Bitget
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting - The Manila Times
Hedge Fund Moves: Can Humacyte Inc deliver consistent EPS growthTrade Ideas & Accurate Trade Setup Notifications - baoquankhu1.vn
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Symvess Battlefield Trauma Potential - Yahoo Finance
Humacyte Shares Surge on US Defense Funding News - StocksToTrade
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Humacyte promotes critical role of vascular health in February - Traders Union
Is Humacyte Inc. backed by strong institutional buyingWeekly Trade Recap & Proven Capital Preservation Methods - mfd.ru
Surprises Report: Whats the fair value of Humacyte Inc stock2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Chart Watch: Why Humacyte Inc. Equity Warrant stock remains on buy listsRate Hike & Reliable Breakout Forecasts - mfd.ru
Can Humacyte Inc. sustain earnings growthQuarterly Trade Review & High Conviction Investment Ideas - mfd.ru
Does Humacyte Inc. Equity Warrant stock benefit from AI growth2025 Sector Review & Free Risk Controlled Daily Trade Plans - mfd.ru
Is Humacyte Inc. a speculative investmentJuly 2025 Intraday Action & Stepwise Trade Execution Plans - mfd.ru
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Battlefield Vascular Repair Potential - Sahm
HUMA stock just shot up 12% today – here’s everything to know about the DOD funding fueling the surge - MSN
Aug Levels: Should I invest in Humacyte Inc Equity Warrant before earnings - baoquankhu1.vn
Sell Signal: Can Humacyte Inc deliver consistent EPS growthJuly 2025 Analyst Calls & Weekly High Return Opportunities - baoquankhu1.vn
Why Humacyte (HUMA) Is Up 5.1% After New DoD Funding Backs Symvess Trauma Use - simplywall.st
Bond Watch: Can Humacyte Inc deliver consistent EPS growthWeekly Investment Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
HUMA Stock Soars Amid Strategic Business Moves and Financial Outlook - StocksToTrade
HUMA Stock Shows Volatility Amid Speculation and Economic Factors - timothysykes.com
Why Humacyte (HUMA) Is Up 19.6% After New DoD Funding For Biologic Vascular Repair - Yahoo Finance
Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist (NASDAQ:HUMA) - Seeking Alpha
Humacyte rises on Department of Defense funding for lab-made blood vessels - TradingView
Humacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral Capital - MarketBeat
BTIG reiterates Buy rating on Humacyte stock amid DoD funding news - Investing.com
Humacyte Secures DOD Funding for Bioengineered Blood Vessels - Intellectia AI
HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge - Stocktwits
Humacyte says new U.S. law backs bioengineered vessels (HUMA) - Seeking Alpha
Humacyte announces new U.S. Department of Defense funding for procurement of bioengineered blood vessels - marketscreener.com
Humacyte Says US DoD to Provide Funding for Procurement of Bioengineered Blood Vessels; Shares Rise - marketscreener.com
Humacyte Announces New U.S. Department Of Defense Funding For Procurement Of Bioengineered Blood Vessels - TradingView
Humacyte stock jumps after securing DoD funding for vascular repair tech - Investing.com
HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge - Asianet Newsable
Pentagon backs lab-grown blood vessels for wounded troops - Stock Titan
RSI Check: Can Humacyte Inc sustain its profitabilityJuly 2025 Short Interest & Verified Stock Trade Ideas - baoquankhu1.vn
Breakouts Watch: Will Humacyte Inc benefit from rising consumer demandMarket Growth Review & High Win Rate Trade Tips - baoquankhu1.vn
Humacyte set to unveil advances in vascular surgery innovation - Traders Union
Macro Review: Will Humacyte Inc benefit from green energy policiesWeekly Loss Report & Weekly High Return Opportunities - baoquankhu1.vn
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Does Humacyte Inc Equity Warrant have declining or rising EPSBuy Signal & Daily Momentum Trading Reports - baoquankhu1.vn
Humacyte, Inc. (HUMA) Stock Analysis: Biotechnology Innovator with a 648% Potential Upside - DirectorsTalk Interviews
Is Humacyte Inc. Equity Warrant in a long term uptrendTrade Risk Assessment & Technical Pattern Based Buy Signals - mfd.ru
Is Humacyte Inc. stock forming a triangle patternBull Run & Advanced Swing Trade Entry Plans - Mfd.ru
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):